Suphil Philipose (@Suphee33) header
Suphil Philipose (@Suphee33) profile picture

🎯 Entrepreneur 🏴󠁧󠁢󠁥󠁮󠁧󠁿

United Kingdom
Joined April 2010
Photo by Suphil Philipose (@Suphee33)Photo by Suphil Philipose (@Suphee33)Photo by Suphil Philipose (@Suphee33)Photo by Suphil Philipose (@Suphee33)Photo by Suphil Philipose (@Suphee33)Photo by Suphil Philipose (@Suphee33)Photo by Suphil Philipose (@Suphee33)Photo by Suphil Philipose (@Suphee33)Photo by Suphil Philipose (@Suphee33)Photo by Suphil Philipose (@Suphee33)
May all beings everywhere be happy and free 🪷 And may the thoughts, words, and actions of my own life contribute in some way to that happiness and to that freedom for all 🪷 Lokah 🪷 Samastah 🪷 Sukhino 🪷Bhavantu 🪷
1
3
1,709
Suphil Philipose retweeted
Replying to @simonmaechling
Generalizing the chemical industry, instead of applying it to the context, isn't a smart move. I'm from italy and we still go buy fresh veggies and fruits from the local shop and fresh meat from the butcher. At the same time I don't blame the chemical industry for cleaning products or batteries manufacturing. Being able to distinguish and to contextualize is a great skill.
1
1
6
84
Suphil Philipose retweeted
Most aging research assumes a gradual decline. A longitudinal Stanford study tracking 108 people aged 25 to 75 found the opposite—two distinct waves of abrupt biomolecular change that hit around the mid-40s and early 60s. The traditional damage-accumulation model treats aging as oxidative stress, DNA mutations, and cellular dysfunction slowly building up over decades. The quasi-programmed framework argues that biological pathways optimized for growth and reproduction become dysregulated after reproductive years, driving hyperactive mTOR signaling and chronic inflammation. Both frameworks miss something critical. Aging isn't linear. Researchers used multi-omics technologies—transcriptomics measuring gene expression, proteomics tracking protein abundance and function, and metagenomics characterizing gut microbiome composition—to monitor blood and microbiome samples at regular intervals. The goal was to identify non-linear transitions in biomolecular profiles that signal pivotal moments in the aging process. They found two distinct waves. The first wave arrives around the mid-40s. Lipid metabolism shifts. ApoA1, the protein that packages HDL cholesterol and removes excess lipids from arterial walls, declines. ApoB, the protein that packages LDL particles carrying cholesterol into tissues, rises. This creates an environment that promotes cardiovascular disease. At the same time, senescent cells accumulate. These are dysfunctional cells that have exited the cell cycle but persist in tissues. They adopt a senescence-associated secretory phenotype, releasing pro-inflammatory cytokines, chemokines, and proteases. While senescence prevents damaged cells from proliferating, the chronic presence of SASP creates a self-reinforcing cycle—inflammation triggers tissue damage, which produces more senescent cells, which amplify inflammation. This state of chronic low-grade inflammation is called inflammaging, and it becomes a hallmark feature of the mid-40s wave. It doesn't just correlate with age-related disease. It drives cardiovascular disease, type 2 diabetes, and neurodegeneration by creating systemic dysfunction that compounds over time. The gut microbiome also shifts during this period. Beneficial bacteria decline. Harmful species increase. This dysbiosis triggers systemic inflammation and insulin resistance, further exacerbating metabolic syndrome risk. The microbiome changes aren't just correlates of inflammation—they contribute to it by disrupting gut barrier integrity and allowing bacterial endotoxins to leak into circulation. The second wave hits around the early 60s. Immune function declines through a process called immunosenescence, where the immune system loses its ability to mount effective responses to infections while simultaneously maintaining chronic inflammation. The result is a system that's both less responsive to pathogens and more inflammatory at baseline. Carbohydrate metabolism deteriorates. Insulin resistance becomes more pronounced due to impaired glucose uptake in muscle and adipose tissue. Blood sugar rises. Metabolic syndrome risk escalates. Cardiovascular risk compounds. Kidney function declines measurably. Glomerular filtration rate drops. Serum creatinine levels rise. The kidneys lose their ability to efficiently filter waste and maintain fluid balance, creating additional strain on cardiovascular and metabolic systems that are already compromised. The gut microbiome undergoes further dysregulation during the second wave. Microbial diversity declines. Beneficial bacteria like Bacteroidetes and Firmicutes decrease. Harmful bacteria like Proteobacteria increase, creating a pro-inflammatory environment. Gut barrier dysfunction worsens, allowing lipopolysaccharides to leak into the bloodstream and trigger systemic inflammation that contributes to insulin resistance and neurodegeneration. The wave-based model aligns with the quasi-programmed aging framework, which argues that aging results from the dysregulation of biological programs originally optimized for development and reproduction. This concept overlaps with antagonistic pleiotropy—the evolutionary theory that pathways conferring early-life benefits become detrimental later. mTOR and the GH/IGF-1 axis are examples. These pathways drive growth and development during youth. They become maladaptive with age, promoting cellular dysfunction, inflammation, and tissue degeneration. Aging isn't random damage accumulation. It's the continuation of intrinsic biological programs operating in an environment they weren't optimized for. This creates intervention opportunities. Rapamycin, an mTOR inhibitor, mitigates overactivation of growth pathways, promotes autophagy, and reduces inflammation. It's been shown to extend healthspan and lifespan across species by resetting dysregulated developmental programs. Strategies that dampen the GH/IGF-1 axis—metformin, canagliflozin, caloric restriction—slow growth processes that accelerate aging and reduce risk of metabolic and degenerative diseases. These interventions target aging at its developmental roots, addressing the programs that drive dysfunction rather than just treating downstream damage. The wave-based model highlights the need for precision health strategies tailored to the biological changes occurring at specific life stages. Biomarker-driven assessments can identify critical risk factors during the mid-40s and early 60s waves, allowing for targeted interventions—rapamycin protocols, metabolic optimization, microbiome restoration—before age-related diseases become clinically apparent. The decisions made during the fourth and fifth decades about metabolic health, inflammation management, and microbiome composition may determine whether the transitions at 45 and 60 represent mild inflection points or catastrophic shifts that compound into chronic disease during the seventh and eighth decades. Aging isn't a gradual decline. It's a series of abrupt, systemic transitions at predictable life stages. The mid-40s and early 60s represent critical windows where biological programs shift from maintaining homeostasis to driving dysfunction. The question is whether interventions targeting these transitions during the wave periods can prevent the compounding damage that defines late-life disease.
11
23
3
116
7,484
Cancer has climbed in younger adults since the mid-1990s while declining in those over 65. People born in the 1990s have at least a fourfold higher risk than those born in the 1960s in several countries; similar increases appear in Asia and elsewhere. scientificamerican.com/artic…
15
Suphil Philipose retweeted
For about 50 years, Alzheimer's research has centered on two proteins: amyloid plaques and tau tangles. A newer theory argues they may be passengers, not drivers, and that the real problem is the brain's energy system. Researchers at the University of Kentucky's Sanders-Brown Center on Aging recently pulled this into one framework called metabolic inflexibility. This is a synthesis of existing evidence, not a single trial. It's a theory, and I'll flag where it's still unproven. First, the brain's fuel problem. Your brain is about 2% of your body weight but burns roughly a fifth of your energy. It also has almost no fuel reserve. Muscle and liver store energy. The brain lives hand to mouth, pulling from your bloodstream second by second. That only works if the brain is flexible. Glucose is its staple, but a healthy brain can switch to backups like lactate and ketones (fuels made from fat) and move energy to whichever regions are working hardest. Think of a hybrid car. Run out of gas and it shifts to the battery. An inflexible brain has lost the battery. What the theory proposes: • Alzheimer's brains show failing glucose use years before symptoms, which is why researchers see energy failure as an early event rather than a late side effect. • The energy failure runs in two phases: an early overheated phase where the brain burns glucose faster than normal, then a later crash into low energy use once compensation runs out. • Immune cells in the brain called microglia switch to a fast, inefficient way of burning glucose when amyloid appears, so they consume far more than their share. • The brain gets about 20% of the body's energy but stores almost none, so neurons starved by that competition have no fallback. • Anti-amyloid drugs, the first to clear plaques from the brain, slow decline without halting it, which fits a disease with more than one engine. How does the cascade work? First, amyloid appears and the microglia mobilize. They shift to the inefficient fuel mode and monopolize the local glucose supply. Second, neurons can't store fuel or easily switch to a backup, so they lose out. Astrocytes, the support cells that normally deliver backup fuel, stop doing it at the same time. Third, the starved, stressed brain makes more amyloid and tau and clears them less well. That worsens the glial crisis and further erodes the ability to switch fuels. The loop feeds itself, which may be why the disease accelerates. This also resolves a puzzle. Brain imaging studies have found Alzheimer's energy use both elevated and depressed. The theory says they were looking at the same disease on opposite sides of the tipping point. What should you do with this? Metabolic flexibility isn't only a brain trait. It's a measurable, trainable property of the whole body that declines with age and metabolic disease. The levers are familiar: • Aerobic exercise builds mitochondria and fat-burning capacity • Resistance training adds muscle that disposes of glucose • Spacing meals and allowing real fasting windows makes your body practice switching fuels • Protecting sleep, and keeping visceral fat, insulin resistance, and inflammation in check The disease people fear most may be continuous with the metabolic health you can already measure and train. The brain may not fail from running out of fuel. It may fail from losing the ability to switch.
9
21
88
4,193
The rise in obesity, diabetes and psychological distress leaves those born in 1970 struggling more in midlife than the previous generation, a study finds

112
124
44
495
1,175,735
Suphil Philipose retweeted
This is one of the more rational takes from an Aussie
16
96
14
1,344
188,396
Suphil Philipose retweeted
Your mitochondria can trigger the same inflammatory alarms your immune system uses to fight bacteria. That's because mitochondria are bacteria, or at least they were 1.5 billion years ago. A Nature Reviews Immunology paper maps the molecular mechanisms of how mitochondria control inflammation, the safeguards that normally prevent false alarms, and what happens when those systems fail. The core problem: mitochondria are ancient bacteria that your cells absorbed roughly 1.5 billion years ago. They still carry bacterial signatures. Your immune system evolved to recognize bacterial molecules as threats. When mitochondria get damaged and leak their contents, your immune system can't distinguish between a broken mitochondrion and an actual infection. Mitochondria contain multiple damage-associated molecular patterns, or DAMPs. These are molecules that trigger immune responses when detected outside their normal location: • Mitochondrial DNA (mtDNA): Unmethylated, circular DNA that resembles bacterial genomes • Cardiolipin: A phospholipid normally confined to the inner mitochondrial membrane • N-formyl peptides: Proteins with bacterial-style chemical signatures • ATP and other metabolites: Energy molecules that signal danger when released These molecules activate pattern recognition receptors, the sensors your immune system uses to detect threats. The most studied pathway involves mitochondrial DNA activating a detection system called cGAS-STING. Here's how it works: When mitochondria become damaged, their outer membrane develops holes. Think of it like a breach in a container. The mitochondrial DNA, which normally stays sealed inside, leaks out into the cytosol, the liquid interior of your cell. An enzyme called cGAS patrols the cytosol looking for DNA that shouldn't be there. When it finds mitochondrial DNA floating around, it produces a signaling molecule called cGAMP. This molecule activates another protein called STING, which sits on the endoplasmic reticulum, a membrane network inside cells. STING activation triggers the production of interferons, immune signaling proteins your body normally makes to fight viral infections. Your cell responds to leaked mitochondrial DNA the same way it responds to a virus. A second pathway involves cardiolipin, a fat molecule that normally stays on the inner membrane of mitochondria. When cardiolipin appears on the outer surface or leaks into the cytosol, it activates the NLRP3 inflammasome. This is a multi-protein assembly that acts like an alarm system. Once activated, it produces inflammatory molecules called cytokines, specifically IL-1β, which trigger inflammation throughout surrounding tissue. Your cells have multiple safeguards to prevent mitochondria from triggering these inflammatory pathways: Apoptosis suppresses inflammation. Apoptosis is programmed cell death, a controlled self-destruction process. When a cell commits to dying, it activates enzymes called caspases. These enzymes act like molecular scissors, rapidly cutting up mitochondrial DNA and other inflammatory molecules before they can activate immune sensors. Two key studies demonstrated that strong caspase activation prevents the cGAS-STING pathway from turning on during cell death. Mitophagy removes damaged mitochondria. Mitophagy is selective autophagy, meaning cellular recycling that targets only mitochondria. When mitochondria lose their electrical charge, called membrane potential, or accumulate too much damage, they get tagged with molecular markers. These tags signal cellular machinery to engulf the damaged mitochondrion inside a double-membrane structure called an autophagosome. The autophagosome fuses with a lysosome, which contains digestive enzymes that break down the damaged mitochondrion completely. This happens before its contents can leak out and trigger inflammation. Chromatin packaging inhibits cGAS. Your nuclear DNA is wrapped around proteins called histones and packaged into a structure called chromatin. This packaging prevents cGAS from detecting it. Mitochondrial DNA lacks this protective packaging, which makes it a much stronger activator of cGAS when it reaches the cytosol. This difference explains why leaked mitochondrial DNA triggers inflammation while nuclear DNA, even when exposed during normal cell division, generally does not. The pathological consequences emerge when these safeguards fail or get overwhelmed. Insufficient mitophagy allows damaged mitochondria to accumulate. Their contents gradually leak into the cytosol, triggering chronic low-grade inflammation. This process contributes to age-related inflammatory diseases, neurodegenerative disorders, and metabolic dysfunction. Defective apoptosis prevents proper DAMP degradation. Cells that can't complete programmed death release intact mitochondrial components that activate stronger inflammatory responses. This mechanism appears in some autoimmune conditions where defective clearance of dying cells drives chronic inflammation. Excessive mitochondrial stress overwhelms quality control. When mitochondrial damage happens faster than mitophagy can remove it, cells release mitochondrial DAMPs even with functioning safeguards. This occurs during ischemia-reperfusion injury, severe metabolic stress, and certain infections that specifically target mitochondria. The inflammation can become bidirectional. Inflammatory signals like TNF-α and interferons feed back to impair mitochondrial function, creating cycles where inflammation damages mitochondria and damaged mitochondria amplify inflammation. Several human diseases show clear links to dysregulated mitochondria-driven inflammation: Parkinson's disease involves mitochondrial dysfunction in dopaminergic neurons. Defective mitophagy allows damaged mitochondria to trigger inflammatory responses that accelerate neurodegeneration. Systemic lupus erythematosus shows elevated mtDNA in circulation and enhanced cGAS-STING activation. Defective clearance of dying cells releases mitochondrial contents that drive autoantibody production. COVID-19 severity correlates with cGAS-STING pathway activation. Viral infection triggers mitochondrial DNA release, and excessive type I interferon responses contribute to immunopathology. Cancer cells sometimes exploit insufficient mitochondria-driven inflammation. Tumors with defective inflammatory signaling evade immune surveillance, while therapeutic interventions that trigger controlled mitochondrial DAMP release can enhance anti-tumor immunity. The therapeutic implications point in two directions. For inflammatory diseases, blocking mitochondrial DAMP signaling could reduce pathological inflammation. cGAS-STING inhibitors are in development for autoimmune conditions. Enhancing mitophagy might prevent DAMP accumulation before inflammation starts. For cancer and infections, activating mitochondrial DAMP release could boost immunity. Some chemotherapy drugs work partly by triggering immunogenic cell death that releases mitochondrial DAMPs. Radiation therapy activates similar pathways. The central insight is that mitochondrial quality control and inflammation are mechanistically linked. The same cellular machinery that maintains energy metabolism also determines inflammatory state. When mitochondria function properly and damaged ones get cleared efficiently, inflammation remains appropriately regulated. When quality control fails, mitochondrial DAMPs drive pathological inflammatory responses. Your immune system treats broken mitochondria like invading bacteria because, evolutionarily, that's exactly what they once were. The molecular signatures persist. What determines health versus disease is how effectively your cells maintain mitochondrial integrity and clear damaged mitochondria before they trigger inappropriate immune activation.
12
55
3
223
10,478
Experts in real world sciencemediacentre.org/exper… Meanwhile Crazy person called @thereal_truther below 🤷🏽 👇
This is what happens when someone gets owned. Every expert agrees with ME!
2
1
148
Science self-corrects, but only to those willing to follow the evidence.
🤖 Made with AI
9
Suphil Philipose retweeted
Replying to @KUPERWASSERLAB
Yes. And BTW I wasn't clear in this post but am open to possibility that something could increase cancer risk long term and encourage any such studies. I am always open to anyone laying out hypotheses and testing them (as long as they are recognized as such and the ideas not promoted as truth without substantiation). But I have vehemently spoken out against the "Turbo Cancer" narrative given my 30yrs+ experience in cancer research showing it was impossible for cancer to form and express within that period of time. I have found the rhetoric absurd, and the cherry picked papers used to support the notion also absurdly misinterpreted. It is frustrating to me that so many ideas, even demonstrably false ones, continue to be propagated no matter how much available evidence speaks against them, or how much scientific principles make them completely implausible. But people believe what they want to believe, and social media propagates the belief. Science self-corrects, but only to those willing to follow the evidence.
1
2
1
15
650
Replying to @Suphee33
I agree the rise from the 90s to 2019 should be concerning. But that has nothing to do with the false claim that COVID is increasing cancers. What do you blame for it?
25
He’s half right. Cancer rates have been rising for decades, and ageing explains part of that increase. Where he’s wrong is in unwilling to acknowledge that COVID can accelerate vascular ageing, potentially introducing another risk factor for cancer. academic.oup.com/eurheartj/a…
Replying to @alanbarnard1
Except RATES haven't increased outside of pre-existing trends and catch up after a big drop during the pandemic. The raw case increase is due to an aging population. There's no replicated measurable rise of cancer worldwide post-2020.
2
1
1
5
1,020
Suphil Philipose retweeted
Folic Acid and COVID-19: Could Long-Term Exposure Influence Disease Severity? anetamariamolenda.substack.c…
1
1
41
Suphil Philipose retweeted
The JAMA study estimates vaccines averted ~2.5 million deaths (mostly in those 60+) and ~15 million life-years during 2020-2024, with benefits largely limited to older adults—a minority of the global population. That matches the claim. Original trials and early real-world data (e.g., the Medscape-linked study) reported ~95% efficacy against confirmed symptomatic infection for the ancestral strain. Later studies, including the Nature and CID papers, show much lower or no effectiveness against infection with subsequent variants and boosters, plus associations with higher symptomatic illness risk in some post-pandemic cohorts. Efficacy against severe outcomes in high-risk groups remained more durable early on.
1
1
1
29
Suphil Philipose retweeted
Rabies
A 21-year-old woman died of RABIES. She had taken all 5 anti-rabies vaccine and rabies immunoglobulin after the dog bite. Still died. Here are the real reasons why this happened. 1. Stitching the bite wound
1
2
73
Suphil Philipose retweeted
Long COVID. Part 56. Spike protein. 65 s. Complete in video. @grok Answer under this post so readers can check it. NEW scientific paper pubmed.ncbi.nlm.nih.gov/3961… NEW scientific paper pubmed.ncbi.nlm.nih.gov/3823… NEW scientific paper pubmed.ncbi.nlm.nih.gov/3762… Made with Grok.
6
10
2
29
24,398
This large observational study strengthens earlier data that COVID infection can “wake” latent viruses, linking some of these reactivations to worse acute disease and long COVID. science.org/content/article/…
33